As per the deal, VGX International will receive marketing rights for the vaccines in Asia, except Japan, and will fund IND-enabling and initial phase I and II clinical studies.
Inovio on the other hand will receive payments based on the achievement of clinical milestones and royalties based on sales in the licensed territories.
Synthetic multi-antigen hepatitis C virus (HCV) vaccine targeting the antigens NS3/4A will be the first product to enter clinical testing, which will be delivered with Inovio’s Cellectra delivery device
The positive preclinical results from Inovio’s novel SynCon vaccine targeting NS3/4A support the development of the vaccines.